Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 33

1.

Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy.

Johnson JA, Li JF, Wei X, Lipscomb J, Irlbeck D, Craig C, Smith A, Bennett DE, Monsour M, Sandstrom P, Lanier ER, Heneine W.

PLoS Med. 2008 Jul 29;5(7):e158. doi: 10.1371/journal.pmed.0050158.

2.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
3.

Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis.

Li JZ, Paredes R, Ribaudo HJ, Svarovskaia ES, Metzner KJ, Kozal MJ, Hullsiek KH, Balduin M, Jakobsen MR, Geretti AM, Thiebaut R, Ostergaard L, Masquelier B, Johnson JA, Miller MD, Kuritzkes DR.

JAMA. 2011 Apr 6;305(13):1327-35. doi: 10.1001/jama.2011.375. Review.

4.

Understanding transmitted HIV resistance through the experience in the USA.

Taiwo B.

Int J Infect Dis. 2009 Sep;13(5):552-9. doi: 10.1016/j.ijid.2008.10.008. Epub 2009 Jan 10. Review.

5.

The Role of HIV-1 Drug-Resistant Minority Variants in Treatment Failure.

Stella-Ascariz N, Arribas JR, Paredes R, Li JZ.

J Infect Dis. 2017 Dec 1;216(suppl_9):S847-S850. doi: 10.1093/infdis/jix430. Review.

PMID:
29207001
6.

Diversity of thymidine analogue resistance genotypes among newly diagnosed HIV-1-infected persons.

García-Lerma JG.

J Antimicrob Chemother. 2005 Aug;56(2):265-9. Epub 2005 Jun 10. Review.

PMID:
15951354
7.

HIV-1 antiretroviral resistance: scientific principles and clinical applications.

Tang MW, Shafer RW.

Drugs. 2012 Jun 18;72(9):e1-25. doi: 10.2165/11633630-000000000-00000. Review.

8.

Systematic review to determine the prevalence of transmitted drug resistance mutations to rilpivirine in HIV-infected treatment-naive persons.

Calvez V, Marcelin AG, Vingerhoets J, Hill A, Hadacek B, Moecklinghoff C.

Antivir Ther. 2016;21(5):405-12. doi: 10.3851/IMP3024. Epub 2016 Jan 13. Review.

PMID:
26761642
9.

Minority variants of drug-resistant HIV.

Gianella S, Richman DD.

J Infect Dis. 2010 Sep 1;202(5):657-66. doi: 10.1086/655397. Review.

10.

Do HIV-1 non-B subtypes differentially impact resistance mutations and clinical disease progression in treated populations? Evidence from a systematic review.

Bhargava M, Cajas JM, Wainberg MA, Klein MB, Pant Pai N.

J Int AIDS Soc. 2014 Jul 4;17:18944. doi: 10.7448/IAS.17.1.18944. eCollection 2014. Review.

11.

Basis of selection of first and second line highly active antiretroviral therapy for HIV/AIDS on genetic barrier to resistance: a literature review.

Katusiime C, Ocama P, Kambugu A.

Afr Health Sci. 2014 Sep;14(3):679-81. doi: 10.4314/ahs.v14i3.25. Review.

12.

Impact of human immunodeficiency virus type-1 sequence diversity on antiretroviral therapy outcomes.

Langs-Barlow A, Paintsil E.

Viruses. 2014 Oct 20;6(10):3855-72. doi: 10.3390/v6103855. Review.

13.

HIV-1 genotypic and phenotypic resistance.

Hanna GJ.

Clin Lab Med. 2002 Sep;22(3):637-49. Review.

PMID:
12244590
14.

Primary HIV-1 Drug Resistant Minority Variants.

Chimukangara B, Samuel R, Naidoo K, de Oliveira T.

AIDS Rev. 2017 Apr - Jun;19(2):89-96. Review.

PMID:
28182621
15.

The Evolving Landscape of HIV Drug Resistance Diagnostics for Expanding Testing in Resource-Limited Settings.

Inzaule SC, Hamers RL, Paredes R, Yang C, Schuurman R, Rinke de Wit TF.

AIDS Rev. 2017 Oct-Dec;19(4):219-230. Review.

PMID:
28182618
16.

Current perspectives on HIV-1 antiretroviral drug resistance.

Iyidogan P, Anderson KS.

Viruses. 2014 Oct 24;6(10):4095-139. doi: 10.3390/v6104095. Review.

17.

Genetic Consequences of Antiviral Therapy on HIV-1.

Arenas M.

Comput Math Methods Med. 2015;2015:395826. doi: 10.1155/2015/395826. Epub 2015 Jun 10. Review.

18.

Clinical management of HIV drug resistance.

Cortez KJ, Maldarelli F.

Viruses. 2011 Apr;3(4):347-78. doi: 10.3390/v3040347. Epub 2011 Apr 14. Review.

19.

Promises and pitfalls of Illumina sequencing for HIV resistance genotyping.

Brumme CJ, Poon AFY.

Virus Res. 2017 Jul 15;239:97-105. doi: 10.1016/j.virusres.2016.12.008. Epub 2016 Dec 18. Review.

PMID:
27993623
20.

Deep sequencing for HIV-1 clinical management.

Casadellà M, Paredes R.

Virus Res. 2017 Jul 15;239:69-81. doi: 10.1016/j.virusres.2016.10.019. Epub 2016 Nov 3. Review.

PMID:
27818211

Supplemental Content

Support Center